Valneva SE's basic earnings per share (Basic EPS) for the
three
months ended in Mar. 2026 was €-0.18.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.80.
Valneva SE's EPS (Diluted) for the
three
months ended in Mar. 2026 was €-0.18.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.80.
Valneva SE's EPS without NRI for the
three
months ended in Mar. 2026 was €-0.17.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.81.
During the past 3 years, the average EPS without NRIGrowth Rate was 14.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 20.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Valneva SE's highest 3-Year average EPS without NRI Growth Rate was 95.20% per year. The lowest was -251.80% per year. And the median was -0.75% per year.
Valneva SE (XPAR:VLA) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Valneva SE EPS (Basic) Related Terms
Valneva SE EPS (Basic) Historical Data
* Premium members only.
The historical data trend for Valneva SE's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Valneva SE's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valneva SE (XPAR:VLA) has a EPS (Basic) of €-0.80 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Valneva SE and its competitors.
Is Valneva SE's EPS (Basic) too high?
Valneva SE's current EPS (Basic) is €-0.80. Overall, Valneva SE has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's EPS (Basic) compare to VRTX and REGN?
Valneva SE's EPS (Basic) of €-0.80 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Valneva SE and its competitors. Valneva SE's current EPS (Basic) is €-0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (XPAR:VLA) is currently considered Fairly Valued. The stock's GF Value™ is €2.46, compared to a current price of €2.27 — trading 7.7% below its estimated fair value. The current EPS (Basic) is €-0.80. Valneva SE's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Valneva SE (XPAR:VLA), the current EPS (Basic) is €-0.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (XPAR:VLA) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of €2.27 is trading 7.7% below its estimated GF Value™ of €2.46.
GuruFocus considers Valneva SE to be Fairly Valued.
Key valuation signals for XPAR:VLA:
EPS (Basic): €-0.80
GF Value™: €2.46 vs. price of €2.27 (7.7% below fair value)
No single metric tells the full story. See the XPAR:VLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
62GF Score
Get the complete analysis for XPAR:VLA
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:VLA has been successfully added to your 
